Marwan Zoghbi, MD
Family Medicine · Visalia, CANPI 1598197998
Payments from drug & device makers
Across 366 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$902
- Lilly USA, LLC$850
- Boehringer Ingelheim$612
- GSK$592
- AbbVie$578
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,65599%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,037 |
| AstraZeneca | 31 | $902 |
| Lilly USA, LLC | 54 | $850 |
| Boehringer Ingelheim | 30 | $612 |
| GSK | 38 | $592 |
| AbbVie(2 entities) | 34 | $578 |
| Phathom Pharmaceuticals, Inc. | 12 | $296 |
| Johnson & Johnson | 12 | $289 |
| Amgen | 11 | $231 |
| Bayer | 8 | $184 |
| Astellas Pharma US Inc | 3 | $128 |
| Edwards Lifesciences | 1 | $119 |
| Pfizer | 6 | $114 |
| Novartis | 4 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Abbott | 4 | $78 |
| Ironwood Pharmaceuticals, Inc | 4 | $69 |
| Dexcom, Inc. | 3 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| Lundbeck LLC | 2 | $39 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Seqirus USA Inc | 2 | $35 |
| Merck | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Mimedx Group, Inc. | 1 | $29 |
| Abiomed | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Organon | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,752 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $112,331 |
| JardianceEmpagliflozin | 80 | $82,864 |
| EliquisApixaban | 45 | $58,482 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $48,617 |
| MounjaroTirzepatide | 30 | $46,171 |
| JanuviaSitagliptin Phosphate | 31 | $37,407 |
| RexultiBrexpiprazole | 13 | $28,949 |
| Metformin Hcl | 201 | $28,499 |
| XareltoRivaroxaban | 22 | $27,932 |
| Teriparatide | 11 | $26,427 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $23,200 |
| KerendiaFinerenone | 15 | $22,007 |
| FarxigaDapagliflozin Propanediol | 19 | $18,266 |
| EntrestoSacubitril/Valsartan | 17 | $16,584 |
| RybelsusSemaglutide | 11 | $15,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,037 | $128,02681 claims |
| Boehringer IngelheimJardiance, Tradjenta | $612 | $93,00692 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $592 | $71,81788 claims |
| Lilly USA, LLCMounjaro, Trulicity | $850 | $59,78543 claims |
| PfizerEliquis | $114 | $58,48245 claims |
| MerckJanuvia | $31 | $37,40731 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $902 | $33,73342 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $84 | $28,94913 claims |
| Johnson & JohnsonXarelto | $289 | $27,93222 claims |
| BayerKerendia | $184 | $22,00715 claims |
| NovartisEntresto | $94 | $16,58417 claims |
| AbbVieLinzess | $578 | $11,77211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Visalia
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.